General Information
Version
4.3
Revision date
2024-08-31
Product name
Giotrif Tablets
Product Synonyms
Giotrif®, film-coated tablets 20mg, 30mg, 40mg + 50 mg
1.2.1 Relevant identified uses
Pharmaceutical
1.2.2. Uses advised against
Safety Data Sheet only for the professional user on use
Emergency telephone
+498007790900, +1 703-527-3887, +49800 1817059
Icons in SDS
Company Information
company name
Boehringer Ing. Pharma GmbH & Co. KG
e-mail address of the competent person responsible for the Safety Data Sheet
EHS-Services@Boehringer-Ingelheim.com
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H319, H361d, H362, H372, H411
Hazard statements
Code
Statements
H319
Causes serious eye irritation
Section 2
SECTION 2: Hazards identification
Regulation (EC) No. 1272/2008 Classification of the substance or mixture
Signal word
Danger
Hazard statements
H319 Causes serious eye irritation. H361d Suspected of damaging the unborn child. H362 May cause harm to breast-fed children. H372 Causes damage to organs (Skin, Gastro-intestinal system) through prolonged or repeated exposure. H411 Toxic to aquatic life with long lasting effects.
Prevention
P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. P260 Do not breathe dust. P263 Avoid contact during pregnancy and while nursing. P273 Avoid release to the environment. P280 Wear protective gloves/ protective clothing/ eye protection/ face protection/ hearing protection.
Response
P391 Collect spillage.
Hazardous Ingredients
Afatinib dimaleate
Additional information
EUH212 Warning! Hazardous respirable dust may be formed when used. Do not breathe dust.
2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumula- tive and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
ECOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regu- lation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
TOXICOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher. The pharmacological effect of the medicament has to be considered (see package leaflet). This drug is not subject to the labelling requirements under the Globally Harmonized System (GHS)
2.1 Classification of the substance or mixture
Classification (REGULATION (EC) No 1272/2008) Eye irritation, Category 2 H319: Causes serious eye irritation. Reproductive toxicity, Category 2 H361d: Suspected of damaging the unborn child. Effects on or via lactation H362: May cause harm to breast-fed children. Specific target organ toxicity - repeated H372: Causes damage to organs through pro- exposure, Category 1, Skin, Gastro- longed or repeated exposure. intestinal system Long-term (chronic) aquatic hazard, Cat- H411: Toxic to aquatic life with long lasting effects. egory 2